Phase II clinical trial of didemnin B in patients with recurrent or refractory anaplastic astrocytoma or glioblastoma multiforme (NSC 325319)

Invest New Drugs. 1999;17(2):179-82. doi: 10.1023/a:1006379402114.

Abstract

The activity of didemnin B, a natural product derived from the Caribbean Tunic was assessed in 16 patients with Glioblastoma multiforme. Didemnin B was administered intravenously by a short infusion at a dose of 4.3 mg/m2 and subsequently escalated to 6.3 mg/m2. No anti-tumor activity was observed. Toxicity consisted of fatigue, weakness, stomatitis, mild blood count changes, nausea and vomiting and occasional fever. Based on these results further studies with didemnin B in patients with Glioblastoma multiforme are not recommended.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II

MeSH terms

  • Adult
  • Aged
  • Anaplasia / pathology
  • Anaplasia / prevention & control
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Astrocytoma / drug therapy*
  • Depsipeptides*
  • Female
  • Glioblastoma / drug therapy*
  • Humans
  • Male
  • Middle Aged
  • Peptides, Cyclic / adverse effects*
  • Peptides, Cyclic / therapeutic use*
  • Recurrence
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Depsipeptides
  • Peptides, Cyclic
  • didemnins